Alzheimer candidate LMTX® inhibits α-sync aggregation in pre-clinical Parkinson’s Disease study
Jan 25 - 2018 03:20 PM
TauRx Therapeutics Ltd has reported preclinical study results, published online in Frontiers in Molecular Neuroscience
Second Phase 3 Study Results for LMTX® published in the Journal of Alzheimer’s Disease
Nov 27 - 2017 12:28 PM
ABERDEEN, Scotland and Singapore, November 27, 2017 – TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer’s disease, published online in the Journal of Alzheimer’s Disease.
TRx-237-005 Phase 3 Clinical Trial
Dec 17 - 2016 12:00 AM
Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 trial in Alzheimer’s disease, study TRx-237-005, were presented at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016 meeting in San Diego, CA, USA.1
TRx-237-015 Publication Update
Nov 16 - 2016 11:05 AM
ABERDEEN, Scotland and Singapore, 16th November 2016 – Following presentation of top-line results from its TRx-237-015 Phase 3 clinical trial in Alzheimer’s disease at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto, Canada in July, TauRx today confirms publication of the full study results in The Lancet.
TRx-237-007 Phase 3 Clinical Trial Update
Sep 04 - 2016 05:15 PM
ABERDEEN, Scotland and Singapore, 4th September 2016 – TauRx Therapeutics Ltd today announced that its TRx-237-007 Phase 3 clinical trial of the company’s second generation tau aggregation inhibitor, LMTX®, in 220 subjects with behavioural variant frontotemporal dementia (bvFTD) failed to achieve its co-primary endpoints.